SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive: PPAR-α agonists significantly enhanced the anti-leukemic effects of imatinib in KCL22 cells and CD34+ primary cells through upregulating human organic cation transporter (hOCT1) gene expression and increasing the uptake of imatinib by CML cells [103].